CLINICAL TRIALS
Sutro is passionately committed to innovation, collaboration, and community.
At Sutro Biopharma, we are committed to finding new therapies to treat serious illnesses. And one of the most crucial steps in this process is the clinical trial. We are grateful to our patients who receive our investigational cancer drug candidates. Without their selflessness and bravery, we couldn’t bring potentially life-saving treatments to market. We know the clinical trial process can be a long and careful one, but we remain dedicated to this critical work. Thank you to all the patients, their families and clinicians who are helping us move forward in this fight.
About Clinical Trials
Sutro Biopharma is committed to developing therapies that can make a difference in people's lives. One of the most critical steps is clinical trials, where we work with patients to study the safety and effectiveness of experimental therapies. We're grateful to those who participate in these trials, as they are the ones who help us bring new treatments to patients. We are dedicated to ensuring these trials are conducted with integrity and respect. If you're interested in learning more about clinical trials, we encourage you to reach out.
Clinical Trial Diversity and Representation
Our mission at Sutro Biopharma is to serve all patients, and to do that well, we must ensure that everyone has equal access to clinical trials. That's why we're committed to addressing underrepresentation of minorities and other groups in these trials. We know that this is an important issue, and we want to be a part of the solution. By working together and taking action, we can help to make a real difference. Join us in this effort to make healthcare more equitable for all.
Find A Trial
Sutro Biopharma is advancing its clinical trials to develop life-changing treatments for patients in need. Stay up to date on the latest progress and information by referring to www.clinicaltrials.gov. We are committed to providing the healthcare community and patients with the most current updates on our trials. Together, we can advance medical research and improve patient outcomes.
Sutro is currently advancing clinical-stage programs designed to provide patient benefit across multiple areas of unmet need.
STRO-002 PROGRAM
REFRaME-O1
ClinicalTrials.gov Identifier: NCT05870748
A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Status: Recruiting
GM1
ClinicalTrials.gov Identifier: NCT03748186
An Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers.
STRO-002-GM1 is a novel homogeneous antibody drug conjugate using precisely positioned non-natural amino acids.
Status: Currently Not Recruiting
GM2
ClinicalTrials.gov Identifier: NCT05200364
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
Status: Currently Not Recruiting
STRO-001 PROGRAM
BN301
ClinicalTrials.gov Identifier: NCT05611853
An Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Status: Not Yet Recruiting
BCM-1
ClinicalTrials.gov Identifier: NCT03424603
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies.
Received Orphan Drug designation for Multiple Myeloma patients.
Status: Closed for Enrollment
Sutro Biopharma’s investigational products have not been approved by the U.S. Food and Drug Administration or other regulatory authorities. The safety and efficacy of investigational products have not been established.
